Effect of quipazine on rat plasma prolactin levels

Herbert Y. Meltzer; Victor S. Fang; Steven M. Paul; Rita Kaluskar

doi:10.1016/0024-3205(76)90300-3

Effect of quipazine on rat plasma prolactin levels

Herbert Y. Meltzer^*, Victor S. Fang, Steven M. Paul, Rita Kaluskar

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Quipazine (2-(1-piperazinyl) quinoline maleate), a serotonin agonist which also has other effects on serotonin metabolism, in doses from 2.5 - 20 mg/kg, i.p., was found to markedly increase plasma prolactin levels in male rats. This increase was blocked by the serotonin antagonists methysergide and brom-lysergic acid diethylamide and potentiated by para-chlorophenylalanine, an inhibitor of serotonin synthesis. These findings suggest that the increase in plasma prolactin levels is due to the serotonin agonist properties of quipazine. Apomorphine and 2-Br-α-ergocryptine pretreatment blocked the effect on plasma prolactin of quipazine, while apomorphine given 15 min after quipazine brought about a rapid decline in the elevated plasma prolactin levels produced by quipazine.

Original language	English (US)
Pages (from-to)	1073-1078
Number of pages	6
Journal	Life Sciences
Volume	19
Issue number	7
DOIs	https://doi.org/10.1016/0024-3205(76)90300-3
State	Published - Oct 1 1976

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/0024-3205(76)90300-3

Cite this

@article{37ec4195301c409fb598bb4c51e587cd,

title = "Effect of quipazine on rat plasma prolactin levels",

abstract = "Quipazine (2-(1-piperazinyl) quinoline maleate), a serotonin agonist which also has other effects on serotonin metabolism, in doses from 2.5 - 20 mg/kg, i.p., was found to markedly increase plasma prolactin levels in male rats. This increase was blocked by the serotonin antagonists methysergide and brom-lysergic acid diethylamide and potentiated by para-chlorophenylalanine, an inhibitor of serotonin synthesis. These findings suggest that the increase in plasma prolactin levels is due to the serotonin agonist properties of quipazine. Apomorphine and 2-Br-α-ergocryptine pretreatment blocked the effect on plasma prolactin of quipazine, while apomorphine given 15 min after quipazine brought about a rapid decline in the elevated plasma prolactin levels produced by quipazine.",

author = "Meltzer, {Herbert Y.} and Fang, {Victor S.} and Paul, {Steven M.} and Rita Kaluskar",

note = "Funding Information: This research was supported by USPHS of USPHS RSA MH47,808 .",

year = "1976",

month = oct,

day = "1",

doi = "10.1016/0024-3205(76)90300-3",

language = "English (US)",

volume = "19",

pages = "1073--1078",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Effect of quipazine on rat plasma prolactin levels

AU - Meltzer, Herbert Y.

AU - Fang, Victor S.

AU - Paul, Steven M.

AU - Kaluskar, Rita

N1 - Funding Information: This research was supported by USPHS of USPHS RSA MH47,808 .

PY - 1976/10/1

Y1 - 1976/10/1

N2 - Quipazine (2-(1-piperazinyl) quinoline maleate), a serotonin agonist which also has other effects on serotonin metabolism, in doses from 2.5 - 20 mg/kg, i.p., was found to markedly increase plasma prolactin levels in male rats. This increase was blocked by the serotonin antagonists methysergide and brom-lysergic acid diethylamide and potentiated by para-chlorophenylalanine, an inhibitor of serotonin synthesis. These findings suggest that the increase in plasma prolactin levels is due to the serotonin agonist properties of quipazine. Apomorphine and 2-Br-α-ergocryptine pretreatment blocked the effect on plasma prolactin of quipazine, while apomorphine given 15 min after quipazine brought about a rapid decline in the elevated plasma prolactin levels produced by quipazine.

AB - Quipazine (2-(1-piperazinyl) quinoline maleate), a serotonin agonist which also has other effects on serotonin metabolism, in doses from 2.5 - 20 mg/kg, i.p., was found to markedly increase plasma prolactin levels in male rats. This increase was blocked by the serotonin antagonists methysergide and brom-lysergic acid diethylamide and potentiated by para-chlorophenylalanine, an inhibitor of serotonin synthesis. These findings suggest that the increase in plasma prolactin levels is due to the serotonin agonist properties of quipazine. Apomorphine and 2-Br-α-ergocryptine pretreatment blocked the effect on plasma prolactin of quipazine, while apomorphine given 15 min after quipazine brought about a rapid decline in the elevated plasma prolactin levels produced by quipazine.

UR - http://www.scopus.com/inward/record.url?scp=0017096033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017096033&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(76)90300-3

DO - 10.1016/0024-3205(76)90300-3

M3 - Article

C2 - 994712

AN - SCOPUS:0017096033

SN - 0024-3205

VL - 19

SP - 1073

EP - 1078

JO - Life Sciences

JF - Life Sciences

IS - 7

ER -

Effect of quipazine on rat plasma prolactin levels

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this